Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs

Executive Summary

AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.

You may also be interested in...

AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles

Both AstraZeneca’s Tagrisso and Clovis’ rociletinib target metastatic EGFR T790M mutation-positive non-small cell lung cancer. Tagrisso was approved by FDA Nov. 13, while Clovis said its drug would be delayed because mature data showed fewer confirmed responses than earlier data.

AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises

With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.

With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches

U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts